HemCon Announces Further Successful Results from Live Nail Infection Anti-Fungal Study

HemCon Medical Technologies, Inc. has announced results from an independent study investigating the time required to successfully treat fungal infected human nails which is a leading cause of Onychomycosis. The studies were conducted as part of HemCon's continued program of development for a formulation based on its newest proprietary platform technology. The Onychomycosis treatment, Mycosinate™ (formerly known as compound A31S), is available for commercial license and provides a controlled release broad spectrum antimicrobial agent to fight infection.

The independent testing of Mycosinate™ for the treatment of Onychomycosis was performed by MedPharm Ltd, UK using fungal infected human nails under conditions that simulate the clinical situation. This system tests the formulations ability to penetrate the nail and kill the T. Rubrum fungal infection on human nails over a period of time. The results observed indicated complete kill of the fungal infection with the active Mycosinate™ formulation in less than 14 days. Subsequent testing to further define the exact period of time to required kill the nail fungal infection is now under way.

Fungal nail infections affect tens of millions of people worldwide and the market size for its treatment for products is estimated at approximately US$4 billion. It is believed that 6-8 percent of all adults will acquire a fungal nail infection, and Onychomycosis is responsible for nearly 50 percent of reported cases.

"Our third and most advanced anti-fungal study in live human nail infection, combined with earlier successes in nail penetration and human safety, affirms the exceptional promise of relief that Mycosinate™ will offer to millions of Americans afflicted with fungal nail infections," said John W. Morgan, CEO of HemCon. "HemCon will continue to offer new technologies for commercialization that promote safe, effective healing on a global scale."

About HemCon Medical Technologies Inc.
HemCon Medical Technologies Inc., is a leading global developer of advanced medical products designed to improve the standard of patient care. The company is responsible for developing the chitosan-based HemCon dressing used by thousands of military and civilian first responders and is changing wound care best practices in hospital, dental and clinical settings. In addition, HemCon is leading the charge to develop and license unique, life-saving medical advances including Lyophilized Human Plasma and Nanospider™ technologies. HemCon is headquartered in Portland, Ore., with additional commercial operations in Ireland, England, Germany and the Czech Republic. For more information, please visit www.hemcon.com.

Most Popular Now

AstraZeneca enters license agreement with KYM Bios…

AstraZeneca and KYM Biosciences Inc.* have entered into a global exclusive licence agreement for CMG901, a potential first-in-class antibody drug conjugate (ADC) targetin...

Pfizer's elranatamab receives FDA and EMA filing a…

Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the company's Biologics License Application (BLA) ...

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Nanosatellite shows the way to RNA medicine of the…

The RNA molecule is commonly recognized as messenger between DNA and protein, but it can also be folded into intricate molecular machines. An example of a naturally occur...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...

AI conjures proteins that speed up chemical reacti…

For the first time, scientists have used machine learning to create brand-new enzymes, which are proteins that accelerate chemical reactions. This is an important step in...